AI and the Future of Patent Law Firms: Opportunity or Race to the Bottom?

AI and the Future of Patent Law Firms: Opportunity or Race to the Bottom?

Send us Fan Mail [https://www.buzzsprout.com/2373657/fan_mail/new] This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn [https://ipwatchdog.com/people/gene-quinn-3/], speaks with a panel of experts. This conversation was a part of the recent IPWatchdog Artificial Intelligence Masters program, and featured Carlo Cotrone [https://ipwatchdog.com/people/carlo-cotrone/], founder and principal consultant of Quartal IP, Robert Plotkin [https://ipwatchdog.com/people/robert-plotkin/], author, patent attorney and founding partner with Blueshift IP, and John Rogitz [https://ipwatchdog.com/people/john-rogitz/], managing attorney at Rogitz & Associates and a member of the IPWatchdog Advisory Committee. Together, the panel examined the future of patent law firms in an AI-driven marketplace, where in-house legal departments are internalizing more work, expecting greater efficiency, and increasingly questioning traditional outside counsel fee structures. The discussion focused on the operational realities behind the AI hype. While AI can improve research, drafting, analysis, and overall work product quality, the panel emphasized that it is not a magic button and cannot replace expert legal judgment. The most effective use of AI in patent practice is incremental, targeted, and lawyer-directed—more co-pilot than autopilot. Panelists explored the risks created when inventors, clients, or law firms over-rely on AI-generated disclosures, patent application critiques, or claim strategy recommendations, including the potential for increased attorney workload, inventorship complications, technical inaccuracies, and downstream litigation vulnerabilities. The conversation ultimately framed AI as both a market disruptor and a strategic opportunity for patent law firms. Firms that respond defensively or compete solely on price risk being pushed into an unsustainable race to the bottom. Firms that lean into client education, workflow redesign, transparent billing expectations, disciplined AI usage, and higher-value counseling will be better positioned to compete. The panel made clear that AI will not eliminate the need for sophisticated patent counsel; it will expose which firms are genuinely strategic partners and which are merely labor providers. Visit us online at IPWatchdog.com [https://ipwatchdog.com]. You can also visit our channels at YouTube [https://www.youtube.com/@ipwatchdog], LinkedIn [https://www.linkedin.com/company/ipwatchdog-inc/], X [https://twitter.com/ipwatchdog], Instagram [https://www.instagram.com/ipwatchdog/] and Facebook [https://facebook.com/IPWatchdog].

Patents, Property Rights, and What Patent Policy Keeps Getting Wrong

Send us Fan Mail [https://www.buzzsprout.com/2373657/fan_mail/new] This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn [https://ipwatchdog.com/people/gene-quinn-3/], speaks with Kristen Osenga [https://ipwatchdog.com/people/kristen-jakobsen-osenga/], who is the Julie & John Nowak Faculty Research Scholar & Professor of Law and Associate Dean for Academic Affairs at the University of Richmond School of Law. Osenga discusses her path from engineering to patent law, including her time at Finnegan and her clerkship with Judge Richard Linn of the Federal Circuit, and explains how those experiences shaped her strong appreciation for patent owners, innovators, and the real-world consequences of patent policy.  The conversation turns to Osenga’s scholarship, which she describes as focused on identifying what patent law commentators, policymakers, and courts are missing or getting wrong. She discusses her current research into who is actually suing whom in patent litigation, why the “patent troll” narrative has distorted enforcement policy, and how treating non-practicing patent owners as inherently suspect has harmed universities, startups, individual inventors, and small innovators. Quinn and Osenga also examine how large technology companies have successfully framed the patent debate around implementer concerns, often at the expense of innovators whose business model depends on licensing or enforcement rather than manufacturing. The episode also explores standard essential patents, FRAND licensing, injunctions, eBay, competition policy, and the recurring misconception that patents are monopolies. Osenga explains why many anti-patent arguments gain traction because they sound intuitive to the public, even when they are economically or legally incomplete. Quinn and Osenga emphasize that companies are in business to make money, that “free” licensing is rarely actually free, and that strong patent rights remain essential to sustaining innovation. The broader takeaway is that patent policy improves only when judges, policymakers, staffers, commentators, and academics take the time to understand how innovation actually works—and why weakening patent enforcement ultimately undermines the very innovators the system is supposed to protect. Visit us online at IPWatchdog.com [https://ipwatchdog.com]. You can also visit our channels at YouTube [https://www.youtube.com/@ipwatchdog], LinkedIn [https://www.linkedin.com/company/ipwatchdog-inc/], X [https://twitter.com/ipwatchdog], Instagram [https://www.instagram.com/ipwatchdog/] and Facebook [https://facebook.com/IPWatchdog].

Patent Boutiques vs. Big Law: How In-House Teams Allocate Prosecution Work

Send us Fan Mail [https://www.buzzsprout.com/2373657/fan_mail/new] This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn [https://ipwatchdog.com/people/gene-quinn-3/], speaks with Fran Cruz [https://ipwatchdog.com/people/francesca-cruz/], who is Senior Vice President of IP Solutions for Juristat, about how data, AI, and changing corporate economics are reshaping patent prosecution business development. The conversation frames a critical market reality: in-house IP teams are under sustained pressure to reduce spend, consolidate outside counsel rosters, and direct more work to firms that can demonstrate measurable value.  Cruz and Quinn examine recent prosecution-volume trends among the top 50 U.S. patent-filing assignees, with particular focus on whether IP boutiques are gaining ground against Am Law 200 firms. The data suggests the market is not simply shifting from large firms to boutiques, or vice versa. Instead, the dominant trend is client-specific consolidation: companies are moving more work to the best performers already on their existing rosters. The discussion highlights that efficiency metrics—especially average office actions, RCE rates, appeal strategy, 101 rejection outcomes, and cost per patent—are becoming increasingly important alongside allowance rates. Quinn emphasizes that law firms can no longer assume quality alone will carry the day; they need to understand what each client values, whether that is compact prosecution, strategic claim scope, portfolio value, or lower-cost patent-factory type execution. The episode closes with a practical business development playbook for patent firms operating in a cost-sensitive, data-driven market. Cruz urges firms to move beyond generic credentials pitches and instead teach prospective clients something specific about their own portfolios, prosecution patterns, competitors, or cost-saving opportunities. Quinn and Cruz also discuss how AI can sharpen messaging, compress bloated pitch language, improve decks and emails, and help firms articulate a differentiated value proposition in terms that in-house counsel actually care about. The broader takeaway is clear: firms that combine credible data, targeted insight, high-value content, and relationship-driven outreach will be better positioned to win work as in-house teams continue to seek the “best bang for your buck” prosecution partners. Visit us online at IPWatchdog.com [https://ipwatchdog.com]. You can also visit our channels at YouTube [https://www.youtube.com/@ipwatchdog], LinkedIn [https://www.linkedin.com/company/ipwatchdog-inc/], X [https://twitter.com/ipwatchdog], Instagram [https://www.instagram.com/ipwatchdog/] and Facebook [https://facebook.com/IPWatchdog].

Why Drug Development Depends on Patent Protection

Send us Fan Mail [https://www.buzzsprout.com/2373657/fan_mail/new] This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn [https://ipwatchdog.com/people/gene-quinn-3/], speaks with Brent Bellows [https://ipwatchdog.com/people/brent-r-bellows/], a partner with Knowles Intellectual Property Strategies [https://www.kipsllc.com/] (KIPS) in Atlanta, Georgia, who has a Ph.D. from the University of Alabama at Birmingham in human genetics. Brent traces his path from graduate research in medical genetics and tumor-associated antigens to patent law, including his time at King & Spalding, a clerkship in the Northern District of Georgia, and his work today at KIPS on patent prosecution, portfolio strategy, litigation support, licensing, and expert witness matters. The conversation highlights how Brent’s scientific training and litigation-facing experience inform the way he drafts and prosecutes life sciences patents, with a clear focus on how those assets may ultimately perform in district court, ANDA litigation, and biosimilar disputes.  Gene and Brent discuss what judges actually care about in patent cases, including why the story told in the patent application matters, why consistency from prosecution through litigation can be strategically important, and why some issues that loom large for prosecutors may carry less practical weight in court. Brent explains that district court judges often approach inequitable conduct allegations skeptically unless the conduct is truly egregious, and he offers insight into Markman practice, claim construction, and how life sciences disputes differ from many high-tech cases because the science often dictates the shape and value of the patent claims. The conversation then moves into the policy and business realities of pharmaceutical innovation, which dominate more than half of the conversation. Brent discusses a variety of issues including Hatch-Waxman, Orange Book listings, paragraph IV certifications, skinny labels, generic entry, clinical trial costs, regulatory exclusivity, and the enormous financial risk associated with bringing new drugs to market. Gene and Brent explore the tension between public demand for lower drug prices and the need for durable incentives that make high-risk drug development economically viable, particularly for oncology, Alzheimer’s, Parkinson’s, antibiotic resistant bacteria, and other difficult-to-treat conditions. The episode closes with a broader innovation-policy message: patents are not a peripheral feature of drug development—they are a core operating asset that enables private-sector investment, supports breakthrough therapies, and ultimately drives the availability of future generic medicines. Visit us online at IPWatchdog.com [https://ipwatchdog.com]. You can also visit our channels at YouTube [https://www.youtube.com/@ipwatchdog], LinkedIn [https://www.linkedin.com/company/ipwatchdog-inc/], X [https://twitter.com/ipwatchdog], Instagram [https://www.instagram.com/ipwatchdog/] and Facebook [https://facebook.com/IPWatchdog].

Proactive IP Risk Management: A Patent Litigator’s Perspective

Send us Fan Mail [https://www.buzzsprout.com/2373657/fan_mail/new] This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn, speaks with Hilary Preston, partner at Vinson & Elkins and co-head of its intellectual property and technology litigation practice. Preston outlines her evolution from a general litigator into a leading IP strategist, highlighting how deep technical fluency—grounded in her physics background—became a competitive differentiator in high-stakes disputes. The discussion traces structural shifts in patent litigation over the past two decades, including venue realignment, the rise of specialized judicial expertise, Judge Alan Albright’s tenure in the Western District of Texas, and the likely impact Albright's resignation will have on patent litigation for years to come. The conversation then pivots to what Preston characterizes as “innovation governance”—a holistic operating model that integrates risk assessment, mitigation, licensing strategy, and, when necessary, litigation. Rather than positioning herself as a “sports” or “media” lawyer, Preston explains her practice as technology-centric problem solving across industries, which include the sports and entertainment industries. She details how legal teams must move upstream—anticipating IP risk in streaming platforms, content delivery architectures, and digital ecosystems—while maintaining alignment with core business objectives. Quinn and Preston converge on a critical insight: high-value counsel is defined less by discrete legal outputs and more by the ability to diagnose underlying business problems and deliver actionable, forward-looking solutions. Finally, the discussion addresses emerging pressure points shaping the next phase of IP and technology. Preston identifies artificial intelligence not just as a software issue, but as an infrastructure challenge—driving massive investment in data centers, energy systems, and associated IP frameworks. This shift is already catalyzing new ownership disputes and litigation vectors. Looking ahead, both Quinn and Preston spotlight unresolved policy tensions, particularly around injunctions and their role in balancing innovation incentives against market competition. The takeaway is clear: as technology complexity scales, the IP function is transitioning from reactive enforcement to strategic governance—requiring practitioners who can operate at the intersection of law, engineering, and enterprise strategy. Visit us online at IPWatchdog.com [https://ipwatchdog.com]. You can also visit our channels at YouTube [https://www.youtube.com/@ipwatchdog], LinkedIn [https://www.linkedin.com/company/ipwatchdog-inc/], X [https://twitter.com/ipwatchdog], Instagram [https://www.instagram.com/ipwatchdog/] and Facebook [https://facebook.com/IPWatchdog].